Novartis Financial Results – Q3 2026
Novartis announces the company’s financial results for the third quarter of 2026.
Latest news
Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS)
New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)
Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity
30 years of Novartis, powered by 250 years of innovation
Rooted in a legacy of scientific discovery, Novartis continues to advance breakthrough medicines that redefine the future of care for patients.
Annual reporting suite
Explore and download our Annual Report 2025, Report on Nonfinancial Matters 2025 and other reporting documents.